Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE)
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the International AIDS Society"
DOI: 10.1002/jia2.26003
Abstract: CUSTOMIZE evaluated the implementation of long‐acting (LA) cabotegravir + rilpivirine, a novel healthcare provider–administered injectable antiretroviral therapy regimen, in diverse US healthcare settings. Findings from staff‐study participants (SSPs) through 12 months of implementation are reported. read more here.
Keywords: acting cabotegravir; implementation long; healthcare settings; long acting ... See more keywords
Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "Reviews in medical virology"
DOI: 10.1002/rmv.2460
Abstract: WHO guidelines recommend daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for pre-exposure prophylaxis (PrEP) of HIV in people at high risk of HIV infection. However, due to social, psychological and other reasons, the… read more here.
Keywords: meta analysis; hiv; acting cabotegravir; long acting ... See more keywords
Long-Acting Cabotegravir for HIV/AIDS Prophylaxis.
Sign Up to like & getrecommendations! Published in 2021 at "Biochemistry"
DOI: 10.1021/acs.biochem.1c00157
Abstract: The retrovirus HIV-1 is the etiological agent of the decades-long AIDS pandemic. Although vaccination is the most common preexposure route to prevent acquisition of viral disease, scalable efficacious vaccination strategies have yet to be developed… read more here.
Keywords: acting cabotegravir; hiv aids; long acting; hiv ... See more keywords
Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac230
Abstract: Abstract Long-acting cabotegravir (CAB-LA) provides an exciting new option for pre-exposure prophylaxis (PrEP) in multiple populations. In this Perspective, we consider the unique pharmacokinetics of CAB-LA and the potential impact on the prescribing of CAB-LA,… read more here.
Keywords: option; acting cabotegravir; exposure prophylaxis; pre exposure ... See more keywords